Reposted by MRC Biostatistics Unit
Stef Baas and colleagues argue that ethics must take a central stage when deciding whether to select a fixed or an adaptive design for a randomized clinical trial. Commentaries provided by Janet Wittes and Stephen Senn. @mrc-bsu.bsky.social @cancerethicsdoc.bsky.social @stephensenn.bsky.social